帕博利珠单抗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "帕博利珠单抗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
3,984th place
1,603rd place
5,225th place
4,888th place
3,823rd place
3,456th place
54th place
88th place
6th place
4th place
low place
low place
11th place
332nd place
low place
low place
low place
low place
274th place
320th place
102nd place
492nd place
3,257th place
3,896th place
low place
low place
low place
low place
low place
7,315th place
234th place
227th place
low place
low place
low place
low place
30th place
111th place
low place
low place
9,274th place
low place
2,614th place
6,491st place
ama-assn.org (Global: 3,257th place; Chinese: 3,896th place)
searchusan.ama-assn.org
- Statement on a Nonproprietary Name Adopted by the USAN Council (PDF). 2013-11-27 [2019-09-08]. （原始内容存档 (PDF)于2020-10-26）.
archive.org (Global: 6th place; Chinese: 4th place)
- Hamid, O; et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine. 2013, 369 (2): 134–44. PMC 4126516
. PMID 23724846. doi:10.1056/nejmoa1305133. - Nghiem. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med. 2016, 374 (26): 2542–2552. PMC 4927341 . PMID 27093365. doi:10.1056/NEJMoa1603702.
bbc.co.uk (Global: 8th place; Chinese: 32nd place)
- Roberts M. NHS reaches deal for life-saving breast-cancer drug. BBC News Online. 2022-11-07 [2022-11-11]. （原始内容存档于2022-11-11）.
canada.ca (Global: 1,712th place; Chinese: 3,316th place)
- Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 2016-05-04 [2024-04-07]. （原始内容存档于2020-02-20）.
cancernetwork.com (Global: low place; Chinese: 7,315th place)
- FDA Approves Anti-PD-1 Drug for Advanced Melanoma. cancernetwork.com. [2019-09-08]. （原始内容存档于2016-01-10）.
clinicaltrials.gov (Global: 5,225th place; Chinese: 4,888th place)
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001). [2019-09-08]. （原始内容存档于2020-10-24）.
- National Cancer Institute (NCI). A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (报告). ClinicalTrials.gov. 13 May 2023 [2024-06-19]. （原始内容存档于2024-06-19）.
|issue=被忽略 (帮助) - A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301). [2019-09-08]. （原始内容存档于2021-01-08）.
- Clinical trial number NCT02752074 for "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)" at ClinicalTrials.gov
- Clinical trial number NCT03914612 for "A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer" at ClinicalTrials.gov
doi.org (Global: 2nd place; Chinese: 23rd place)
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. 2017, 18 (12): e731–e741. PMID 29208439. doi:10.1016/s1470-2045(17)30607-1 （英语）.
- World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.
- Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals //www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295
|PMC=缺少标题 (帮助). November 2020, 13 (11): 373. PMC 7695295. PMID 33171686. doi:10.3390/ph13110373 . - Redman, Jason M.; Gibney, Geoffrey T.; Atkins, Michael B. Advances in immunotherapy for melanoma. BMC Medicine. 2016-02-06, 14 (1): 20. PMC 4744430 . PMID 26850630. doi:10.1186/s12916-016-0571-0.
- Fuereder, Thorsten. Immunotherapy for head and neck squamous cell carcinoma. Memo - Magazine of European Medical Oncology. 2016-06-20, 9 (2): 66–69. PMC 4923082 . PMID 27429658. doi:10.1007/s12254-016-0270-8.
- Chen, Hongbin; Vachhani, Pankit. Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy. September 2016, 9: 5855–5866. PMC 5045223 . PMID 27713639. doi:10.2147/ott.s97746.
- Linardou, Helena; Gogas, Helen. Toxicity management of immunotherapy for patients with metastatic melanoma. Annals of Translational Medicine. July 2016, 4 (14): 272. PMC 4971373 . PMID 27563659. doi:10.21037/atm.2016.07.10.
- The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. Jul 2010, 236: 219–42. PMC 2919275 . PMID 20636820. doi:10.1111/j.1600-065X.2010.00923.x.
- Buqué, Aitziber; et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology. 2 March 2015, 4 (4): e1008814. PMC 4485728 . PMID 26137403. doi:10.1080/2162402x.2015.1008814.
- Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. Mar 22, 2012, 12 (4): 252–64. PMC 4856023 . PMID 22437870. doi:10.1038/nrc3239.
- Hamid, O; et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine. 2013, 369 (2): 134–44. PMC 4126516 . PMID 23724846. doi:10.1056/nejmoa1305133.
- Ledford, Heidi. News: Tissue-independent cancer drug gets fast-track approval from US regulator. Nature. 24 May 2017 [2019-09-08]. doi:10.1038/nature.2017.22054. （原始内容存档于2020-11-12）.
- Nghiem. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med. 2016, 374 (26): 2542–2552. PMC 4927341 . PMID 27093365. doi:10.1056/NEJMoa1603702.
- Le, DT; Durham, JN; Smith, KN; Wang, H; Bartlett, BR; Aulakh, LK; Lu, S; Kemberling, H; Wilt, C. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade.. Science. 8 June 2017, 357 (6349): 409–413. PMC 5576142 . PMID 28596308. doi:10.1126/science.aan6733.
- Syn NL, Teng MW, Mok TS, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. December 2017, 18 (12): e731–e741. PMID 29208439. doi:10.1016/s1470-2045(17)30607-1.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Journal of Clinical Oncology //www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089
|PMC=缺少标题 (帮助). July 2021, 39 (21): 2339–2349. PMC 8280089. PMID 33872070. doi:10.1200/JCO.21.00174 . - Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England Journal of Medicine. March 2023, 388 (23): 2159–2170. PMC 10351614 . PMID 36972022. S2CID 257765751. doi:10.1056/NEJMoa2302312.
- Precision medicine meets cancer vaccines. Nature Medicine. June 2023, 29 (6): 1287. PMID 37328586. S2CID 259184146. doi:10.1038/s41591-023-02432-2 .
- Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G. Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines //www.ncbi.nlm.nih.gov/pmc/articles/PMC10057252
|PMC=缺少标题 (帮助). March 2023, 11 (3): 636. PMC 10057252. PMID 36992220. doi:10.3390/vaccines11030636 .
drugs.com (Global: 399th place; Chinese: 208th place)
- Pembrolizumab (Keytruda) Use During Pregnancy. Drugs.com. 2019-09-24 [2020-01-10]. （原始内容存档于2020-06-14）.
- Pembrolizumab Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [2019-07-15]. （原始内容存档于2020-06-14） （英语）.
england.nhs.uk (Global: low place; Chinese: low place)
- NHS strikes deal for potentially life-saving breast cancer drug. NHS England. 2022-11-08 [2024-06-20]. （原始内容存档于2024-06-20）.
europa.eu (Global: 68th place; Chinese: 209th place)
ema.europa.eu
- Keytruda EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-30]. （原始内容存档于2020-05-24）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Assessment report: Keytruda. Procedure No. EMEA/H/C/003820/0000 (PDF). EMA. 2015-05-21 [2019-09-08]. （原始内容存档 (PDF)于2018-06-14）.
- Keytruda index page at EMA. European Medicines Agency. [2016-11-10]. （原始内容存档于2018-06-20）.
fda.gov (Global: 447th place; Chinese: 581st place)
fda.gov
- FDA approves pembrolizumab and berahyaluronidase alfa-pmph. U.S. Food and Drug Administration (FDA). 2025-09-19 [2025-09-21].
- Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma （页面存档备份，存于互联网档案馆）, 2017-03-15, FDA
- Research, Center for Drug Evaluation and. FDA approves pembrolizumab for advanced esophageal squamous cell cancer. FDA. 2019-07-31 [2019-09-08]. （原始内容存档于2020-12-22） （英语）.
- FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Food and Drug Administration. 2017-05-23 [2019-09-08]. （原始内容存档于2019-04-23）.
- Bala, Sanjeeve; Nair, Abhi. Approved Drugs - FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript. FDA. 30 May 2017 [2019-09-08]. （原始内容存档于2019-04-23） （英语）.
- U.S. Food and Drug Administration. FDA approves Keytruda for advanced melanoma. U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2014-09-04 [2015-12-24]. （原始内容存档于2017-03-14）.
- FDA approves Keytruda for advanced non-small cell lung cancer. U.S. Food and Drug Administration. 2015-10-02 [2019-09-08]. （原始内容存档于2018-01-26）.
- FDA approves pembrolizumab for adults and children with TMB-H solid tumors. U.S. Food and Drug Administration (FDA). 2020-06-17 [2020-06-19]. （原始内容存档于2021-03-15）.
- FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage. U.S. Food and Drug Administration (FDA). 2024-01-12 [2024-03-09]. （原始内容存档于2024-06-26）.
本文含有此來源中屬於公有领域的内容。 - FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma. U.S. Food and Drug Administration (FDA). 2024-06-17 [2024-06-18]. （原始内容存档于2024-06-18）. 本文含有此來源中屬於公有领域的内容。
accessdata.fda.gov
- Drug Approval Package: Keytruda (pembrolizumab) Powder for Injection NDA #125514. U.S. Food and Drug Administration (FDA). 2014-10-02 [2025-09-21].
- Pembrolizumab label (PDF). FDA. May 2017 [2019-09-08]. （原始内容存档 (PDF)于2020-10-17）. linked from Index page at FDA website （页面存档备份，存于互联网档案馆） November 2016
- Accelerated approval notice: BLA 125514/S-14 (PDF). FDA. 2017-05-23 [2019-09-08]. （原始内容存档 (PDF)于2021-08-28）.
fiercepharmamarketing.com (Global: low place; Chinese: low place)
- Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto. [2019-09-08]. （原始内容存档于2016-04-01）.
forbes.com (Global: 54th place; Chinese: 88th place)
- Shaywitz, David. The Startling History Behind Merck's New Cancer Blockbuster. Forbes. 2017-07-26.
- Timmerman, Luke. ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate. Forbes. June 2, 2015 [2019-09-08]. （原始内容存档于2020-11-08）.
globenewswire.com (Global: 2,614th place; Chinese: 6,491st place)
- Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with Keytruda (pembrolizumab) (新闻稿). Neoleukin Therapeutics. 2022-01-10 [2025-03-22]. （原始内容存档于2022-02-07） –通过GlobeNewswire.
handle.net (Global: 102nd place; Chinese: 492nd place)
hdl.handle.net
- World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.
hpfb-dgpsa.ca (Global: low place; Chinese: low place)
dhpp.hpfb-dgpsa.ca
- Regulatory Decision Summary for Keytruda. Health Canada. 6 February 2024 [2024-04-02]. （原始内容存档于2024-04-02）.
inventorsdigest.com (Global: low place; Chinese: low place)
- Inventors of the Year. Inventors Digest. [2017-05-08]. （原始内容存档于2020-10-28）.
ktgh.com.tw (Global: low place; Chinese: low place)
- 吉舒達®凍晶注射劑50毫克 (PDF). （原始内容存档 (PDF)于2021-11-24）.
managedcaremag.com (Global: low place; Chinese: low place)
- Adams, Katherine T. Cancer Immunotherapies--and Their Cost--Take Center Stage at ASCO's 2015 Annual Meeting. Managed Care Magazine Online. 24 July 2015 [2019-09-08]. （原始内容存档于2017-12-13）.
medicines.org.uk (Global: 3,823rd place; Chinese: 3,456th place)
- Keytruda 25 mg/mL concentrate for solution for infusion. electronic medicines compendium (emc). 2025-02-25 [2025-03-22]. （原始内容存档于2024-12-11）.
- Pembrolizumab label at eMC. UK Electronic Medicines Compendium. 27 January 2017 [2019-09-08]. （原始内容存档于2017-12-13）.
medpagetoday.com (Global: 9,274th place; Chinese: low place)
- Jenkins, Kristin. Keytruda Impresses in Triple-Negative Breast Cancer. MedPage Today. 5 May 2016 [2019-09-08]. （原始内容存档于2016-12-19）.
merck.com (Global: 6,464th place; Chinese: 3,752nd place)
nature.com (Global: 234th place; Chinese: 227th place)
- Ledford, Heidi. News: Tissue-independent cancer drug gets fast-track approval from US regulator. Nature. 24 May 2017 [2019-09-08]. doi:10.1038/nature.2017.22054. （原始内容存档于2020-11-12）.
nih.gov (Global: 4th place; Chinese: 5th place)
ncbi.nlm.nih.gov
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. 2017, 18 (12): e731–e741. PMID 29208439. doi:10.1016/s1470-2045(17)30607-1 （英语）.
- Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals //www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295
|PMC=缺少标题 (帮助). November 2020, 13 (11): 373. PMC 7695295. PMID 33171686. doi:10.3390/ph13110373 . - Redman, Jason M.; Gibney, Geoffrey T.; Atkins, Michael B. Advances in immunotherapy for melanoma. BMC Medicine. 2016-02-06, 14 (1): 20. PMC 4744430 . PMID 26850630. doi:10.1186/s12916-016-0571-0.
- Fuereder, Thorsten. Immunotherapy for head and neck squamous cell carcinoma. Memo - Magazine of European Medical Oncology. 2016-06-20, 9 (2): 66–69. PMC 4923082 . PMID 27429658. doi:10.1007/s12254-016-0270-8.
- Chen, Hongbin; Vachhani, Pankit. Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy. September 2016, 9: 5855–5866. PMC 5045223 . PMID 27713639. doi:10.2147/ott.s97746.
- Linardou, Helena; Gogas, Helen. Toxicity management of immunotherapy for patients with metastatic melanoma. Annals of Translational Medicine. July 2016, 4 (14): 272. PMC 4971373 . PMID 27563659. doi:10.21037/atm.2016.07.10.
- The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. Jul 2010, 236: 219–42. PMC 2919275 . PMID 20636820. doi:10.1111/j.1600-065X.2010.00923.x.
- Buqué, Aitziber; et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology. 2 March 2015, 4 (4): e1008814. PMC 4485728 . PMID 26137403. doi:10.1080/2162402x.2015.1008814.
- Pardoll, DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. Mar 22, 2012, 12 (4): 252–64. PMC 4856023 . PMID 22437870. doi:10.1038/nrc3239.
- Hamid, O; et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine. 2013, 369 (2): 134–44. PMC 4126516 . PMID 23724846. doi:10.1056/nejmoa1305133.
- Nghiem. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med. 2016, 374 (26): 2542–2552. PMC 4927341 . PMID 27093365. doi:10.1056/NEJMoa1603702.
- Le, DT; Durham, JN; Smith, KN; Wang, H; Bartlett, BR; Aulakh, LK; Lu, S; Kemberling, H; Wilt, C. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade.. Science. 8 June 2017, 357 (6349): 409–413. PMC 5576142 . PMID 28596308. doi:10.1126/science.aan6733.
- Syn NL, Teng MW, Mok TS, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. December 2017, 18 (12): e731–e741. PMID 29208439. doi:10.1016/s1470-2045(17)30607-1.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Journal of Clinical Oncology //www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089
|PMC=缺少标题 (帮助). July 2021, 39 (21): 2339–2349. PMC 8280089. PMID 33872070. doi:10.1200/JCO.21.00174 . - Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England Journal of Medicine. March 2023, 388 (23): 2159–2170. PMC 10351614 . PMID 36972022. S2CID 257765751. doi:10.1056/NEJMoa2302312.
- Precision medicine meets cancer vaccines. Nature Medicine. June 2023, 29 (6): 1287. PMID 37328586. S2CID 259184146. doi:10.1038/s41591-023-02432-2 .
- Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G. Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines //www.ncbi.nlm.nih.gov/pmc/articles/PMC10057252
|PMC=缺少标题 (帮助). March 2023, 11 (3): 636. PMC 10057252. PMID 36992220. doi:10.3390/vaccines11030636 .
dailymed.nlm.nih.gov
- Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution. DailyMed. 2019-09-17 [2020-01-10]. （原始内容存档于2020-06-17）.
semanticscholar.org (Global: 11th place; Chinese: 332nd place)
api.semanticscholar.org
- Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England Journal of Medicine. March 2023, 388 (23): 2159–2170. PMC 10351614 . PMID 36972022. S2CID 257765751. doi:10.1056/NEJMoa2302312.
- Precision medicine meets cancer vaccines. Nature Medicine. June 2023, 29 (6): 1287. PMID 37328586. S2CID 259184146. doi:10.1038/s41591-023-02432-2 .
springer.com (Global: 274th place; Chinese: 320th place)
adisinsight.springer.com
- Pembrolizumab. AdisInsight. [2016-11-05]. （原始内容存档于2017-11-01）.
telegraph.co.uk (Global: 30th place; Chinese: 111th place)
- Roberts L. NHS to treat aggressive form of breast cancer with potentially life-saving drug. The Telegraph. 2022-11-08 [2024-06-20]. （原始内容存档于2024-06-20）.
tga.gov.au (Global: 3,984th place; Chinese: 1,603rd place)
- Keytruda, Microsatellite instability-high cancer. Department of Health and Aged Care, Commonwealth of Australia. （原始内容存档于2022-11-22）.
- Keytruda, Oesophageal Cancer. Department of Health and Aged Care, Commonwealth of Australia. （原始内容存档于2022-11-22）.
- Keytruda (pembrolizumab) is indicated for the adjuvant treatment of adult and adolescent (12 years and older) patients with Stage IIB, IIC, or III melanoma who have undergone complete resection.. Department of Health and Aged Care, Commonwealth of Australia. [2023-03-18]. （原始内容存档于2023-03-18）.
- Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
- Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-31]. （原始内容存档于2024-03-31）.
- KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd) - 26. Department of Health and Aged Care. [2024-09-15]. （原始内容存档于2024-09-15）.
- KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd) - 27. Department of Health and Aged Care. [2024-09-15]. （原始内容存档于2024-09-15）.
thepharmaletter.com (Global: low place; Chinese: low place)
- Merck & Co and Taiho to co-promote cancer immunotherapy pembrolizumab in Japan. The Pharma Letter. 2016-04-13 [2019-09-08]. （原始内容存档于2018-04-18）.
- Merck & Co updates Keytruda findings at ASCO. The Pharma Letter. June 10, 2016 [2019-09-08]. （原始内容存档于2016-11-05）.
thetranslationalscientist.com (Global: low place; Chinese: low place)
- Unlocking Checkpoint Inhibition. Translational Scientist. August 9, 2016 [2019-09-08]. （原始内容存档于2018-11-05）.
web.archive.org (Global: 1st place; Chinese: 1st place)
- Pembrolizumab (Keytruda) Use During Pregnancy. Drugs.com. 2019-09-24 [2020-01-10]. （原始内容存档于2020-06-14）.
- Keytruda, Microsatellite instability-high cancer. Department of Health and Aged Care, Commonwealth of Australia. （原始内容存档于2022-11-22）.
- Keytruda, Oesophageal Cancer. Department of Health and Aged Care, Commonwealth of Australia. （原始内容存档于2022-11-22）.
- Keytruda (pembrolizumab) is indicated for the adjuvant treatment of adult and adolescent (12 years and older) patients with Stage IIB, IIC, or III melanoma who have undergone complete resection.. Department of Health and Aged Care, Commonwealth of Australia. [2023-03-18]. （原始内容存档于2023-03-18）.
- Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
- Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 2022-06-21 [2024-03-31]. （原始内容存档于2024-03-31）.
- KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd) - 26. Department of Health and Aged Care. [2024-09-15]. （原始内容存档于2024-09-15）.
- KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd) - 27. Department of Health and Aged Care. [2024-09-15]. （原始内容存档于2024-09-15）.
- Regulatory Decision Summary for Keytruda. Health Canada. 6 February 2024 [2024-04-02]. （原始内容存档于2024-04-02）.
- Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 2016-05-04 [2024-04-07]. （原始内容存档于2020-02-20）.
- Keytruda 25 mg/mL concentrate for solution for infusion. electronic medicines compendium (emc). 2025-02-25 [2025-03-22]. （原始内容存档于2024-12-11）.
- Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution. DailyMed. 2019-09-17 [2020-01-10]. （原始内容存档于2020-06-17）.
- Keytruda EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-30]. （原始内容存档于2020-05-24）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- 吉舒達®凍晶注射劑50毫克 (PDF). （原始内容存档 (PDF)于2021-11-24）.
- Pembrolizumab. AdisInsight. [2016-11-05]. （原始内容存档于2017-11-01）.
- Pembrolizumab Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [2019-07-15]. （原始内容存档于2020-06-14） （英语）.
- Pembrolizumab label (PDF). FDA. May 2017 [2019-09-08]. （原始内容存档 (PDF)于2020-10-17）. linked from Index page at FDA website （页面存档备份，存于互联网档案馆） November 2016
- Pembrolizumab label at eMC. UK Electronic Medicines Compendium. 27 January 2017 [2019-09-08]. （原始内容存档于2017-12-13）.
- Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma （页面存档备份，存于互联网档案馆）, 2017-03-15, FDA
- Research, Center for Drug Evaluation and. FDA approves pembrolizumab for advanced esophageal squamous cell cancer. FDA. 2019-07-31 [2019-09-08]. （原始内容存档于2020-12-22） （英语）.
- FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Food and Drug Administration. 2017-05-23 [2019-09-08]. （原始内容存档于2019-04-23）.
- Bala, Sanjeeve; Nair, Abhi. Approved Drugs - FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript. FDA. 30 May 2017 [2019-09-08]. （原始内容存档于2019-04-23） （英语）.
- Statement on a Nonproprietary Name Adopted by the USAN Council (PDF). 2013-11-27 [2019-09-08]. （原始内容存档 (PDF)于2020-10-26）.
- Assessment report: Keytruda. Procedure No. EMEA/H/C/003820/0000 (PDF). EMA. 2015-05-21 [2019-09-08]. （原始内容存档 (PDF)于2018-06-14）.
- Unlocking Checkpoint Inhibition. Translational Scientist. August 9, 2016 [2019-09-08]. （原始内容存档于2018-11-05）.
- Inventors of the Year. Inventors Digest. [2017-05-08]. （原始内容存档于2020-10-28）.
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001). [2019-09-08]. （原始内容存档于2020-10-24）.
- U.S. Food and Drug Administration. FDA approves Keytruda for advanced melanoma. U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2014-09-04 [2015-12-24]. （原始内容存档于2017-03-14）.
- FDA Approves Anti-PD-1 Drug for Advanced Melanoma. cancernetwork.com. [2019-09-08]. （原始内容存档于2016-01-10）.
- Keytruda index page at EMA. European Medicines Agency. [2016-11-10]. （原始内容存档于2018-06-20）.
- FDA approves Keytruda for advanced non-small cell lung cancer. U.S. Food and Drug Administration. 2015-10-02 [2019-09-08]. （原始内容存档于2018-01-26）.
- Merck & Co and Taiho to co-promote cancer immunotherapy pembrolizumab in Japan. The Pharma Letter. 2016-04-13 [2019-09-08]. （原始内容存档于2018-04-18）.
- Ledford, Heidi. News: Tissue-independent cancer drug gets fast-track approval from US regulator. Nature. 24 May 2017 [2019-09-08]. doi:10.1038/nature.2017.22054. （原始内容存档于2020-11-12）.
- Accelerated approval notice: BLA 125514/S-14 (PDF). FDA. 2017-05-23 [2019-09-08]. （原始内容存档 (PDF)于2021-08-28）.
- FDA approves pembrolizumab for adults and children with TMB-H solid tumors. U.S. Food and Drug Administration (FDA). 2020-06-17 [2020-06-19]. （原始内容存档于2021-03-15）.
- FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage. U.S. Food and Drug Administration (FDA). 2024-01-12 [2024-03-09]. （原始内容存档于2024-06-26）. 本文含有此來源中屬於公有领域的内容。
- FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma. U.S. Food and Drug Administration (FDA). 2024-06-17 [2024-06-18]. （原始内容存档于2024-06-18）. 本文含有此來源中屬於公有领域的内容。
- National Cancer Institute (NCI). A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (报告). ClinicalTrials.gov. 13 May 2023 [2024-06-19]. （原始内容存档于2024-06-19）.
|issue=被忽略 (帮助) - Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto. [2019-09-08]. （原始内容存档于2016-04-01）.
- NHS strikes deal for potentially life-saving breast cancer drug. NHS England. 2022-11-08 [2024-06-20]. （原始内容存档于2024-06-20）.
- Roberts M. NHS reaches deal for life-saving breast-cancer drug. BBC News Online. 2022-11-07 [2022-11-11]. （原始内容存档于2022-11-11）.
- Roberts L. NHS to treat aggressive form of breast cancer with potentially life-saving drug. The Telegraph. 2022-11-08 [2024-06-20]. （原始内容存档于2024-06-20）.
- Timmerman, Luke. ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate. Forbes. June 2, 2015 [2019-09-08]. （原始内容存档于2020-11-08）.
- Adams, Katherine T. Cancer Immunotherapies--and Their Cost--Take Center Stage at ASCO's 2015 Annual Meeting. Managed Care Magazine Online. 24 July 2015 [2019-09-08]. （原始内容存档于2017-12-13）.
- Jenkins, Kristin. Keytruda Impresses in Triple-Negative Breast Cancer. MedPage Today. 5 May 2016 [2019-09-08]. （原始内容存档于2016-12-19）.
- Merck & Co updates Keytruda findings at ASCO. The Pharma Letter. June 10, 2016 [2019-09-08]. （原始内容存档于2016-11-05）.
- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301). [2019-09-08]. （原始内容存档于2021-01-08）.
- Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with Keytruda (pembrolizumab) (新闻稿). Neoleukin Therapeutics. 2022-01-10 [2025-03-22]. （原始内容存档于2022-02-07） –通过GlobeNewswire.